Is good enough for our peers good enough for policy makers?

Luft HS., Health Serv Res. doi: 10.1111/1475-6773.12750. [Epub ahead of print] , 2017 Sep 04

Abstract

Articles should be research contributions and also impact practice & policy. How is this done for policy-makers, who do not have methodological training or time for literature review?

Topics addressed include: Use Measures That Matter, Assess Plausible Alternatives, and Present Findings Accessibly.

Pubmed Abstract

Pubmed AbstractOpens New Window

Associated Topics

Health Policy

Related Publications

Clopidogrel pharmacogenomics: next steps: a clinical algorithm, gene-gene interactions, and an elusive outcomes trial.

Gladding P1, Panattoni L, Webster M, Cho L, Ellis S.
JACC Cardiovasc Interv. 3(10):995-1000. doi: 10.1016/j.jcin.2010.08.012.
2010 Oct 01

The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.

Panattoni LE.
J Health Econ. 30(1):126-45. doi: 10.1016/j.jhealeco.2010.09.004. Epub 2010 Oct 8.
2011 Jan 01

Medicare annual preventive care visits: use increased among fee-for-service patients, but many do not participate.

Chung S, Lesser LI, Lauderdale DS, Johns NE, Palaniappan LP, Luft HS.
Health Aff (Millwood). 34(1):11-20. doi: 10.1377/hlthaff.2014.0483.
2015 Jan 01

Utilization of cardiac monitoring tests in women with non-metastatic breast cancer treated with trastuzumab.

Shin J, Liang SY, Hassett MJ, Phillips KA, Haas JS.
Personalized Medicine. 10(7): 703-708.
2013 Jan 01

Economic perspectives on personalized health care and prevention.

Phillips KA, Sakowski JA, Liang SY, Ponce NA.
Forum for Health Economics and Policy. 16(2):57–86.
2013 Sep 01